# large B-cell lymphoma FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/large-b-cell-lymphoma

> 9 upcoming FDA catalysts in large B-cell lymphoma: golcadomide (BMY) on Aug to Nov 2027 (topline data readout); golcadomide (BMY) on August 2027 (primary completion); LYL314 (LYEL) on late 2027 (NDA/BLA submission); cemacabtagene ansegedleucel (ALLO) on December 2027 (primary completion); and 5 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| November 13, 2026 | [Xenetic Biosciences, Inc. trial start](https://sec-api.dev/companies/xbio/catalysts) | XBIO | large B-cell lymphoma | completed | "Initiated Clinical Evaluation of DNase I in Combination with CAR T-Cell Therapy: Announced the first patient dosed in an investigator-initiated, Phase I (NCT07361224) clinical study evaluating systemic recombinant human DNase I in combination with anti-CD19 CAR T-cell therapy in patients with large B-cell lymphoma (LBCL)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534525/000168316826008650/xenetic_ex9901.htm)) |
| Aug to Nov 2027 | [Golcadomide topline data readout](https://sec-api.dev/pdufa/golcadomide) | BMY | Large B-cell Lymphoma | scheduled | "NCT06356129 (Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-09 (ESTIMATED); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06356129)) |
| August 2027 | [Golcadomide primary completion](https://sec-api.dev/pdufa/golcadomide) | BMY | Large B-cell Lymphoma | scheduled | "NCT06356129 (Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-09 (ESTIMATED); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06356129)) |
| late 2027 | [LYL314 NDA/BLA submission](https://sec-api.dev/pdufa/lyl314) | LYEL | large B-cell lymphoma | scheduled | "With this private placement, Lyell expects its cash, cash equivalents and marketable securities balances will be sufficient to meet working capital and capital expenditure needs into mid-2027, including through expected data from the LYL314 PiNACLE pivotal trial from which Lyell intends to submit a Biologics License Application later in 2027 for patients with large B-cell lymphoma (LBCL) relapsed and/or refractory to two or more lines of prior therapy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1806952/000119312525164853/d24368dex991.htm)) |
| December 2027 | [Cemacabtagene ansegedleucel primary completion](https://sec-api.dev/pdufa/cemacabtagene-ansegedleucel) | ALLO | Large B-cell Lymphoma | scheduled | "NCT06500273 (Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Allogene Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06500273)) |
| Dec 2027 to Mar 2028 | [Cemacabtagene ansegedleucel topline data readout](https://sec-api.dev/pdufa/cemacabtagene-ansegedleucel) | ALLO | Large B-cell Lymphoma | scheduled | "NCT06500273 (Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Allogene Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06500273)) |
| Jun to Sep 2030 | [AZD0486 topline data readout](https://sec-api.dev/pdufa/azd0486) | AZN | Large B-cell Lymphoma | scheduled | "NCT07215585 (AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-06-10 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07215585)) |
| June 2030 | [AZD0486 primary completion](https://sec-api.dev/pdufa/azd0486) | AZN | Large B-cell Lymphoma | scheduled | "NCT07215585 (AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-06-10 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07215585)) |
| Sep to Dec 2030 | [Surovatamig topline data readout](https://sec-api.dev/pdufa/surovatamig) | AZN | Large B-cell Lymphoma | scheduled | "NCT07911553 (A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-09-02 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07911553)) |
| September 2030 | [Surovatamig primary completion](https://sec-api.dev/pdufa/surovatamig) | AZN | Large B-cell Lymphoma | scheduled | "NCT07911553 (A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-09-02 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07911553)) |

## Drugs

- [Golcadomide](https://sec-api.dev/pdufa/golcadomide) (BMY)
- [LYL314](https://sec-api.dev/pdufa/lyl314) (LYEL)
- [Cemacabtagene ansegedleucel](https://sec-api.dev/pdufa/cemacabtagene-ansegedleucel) (ALLO)
- [AZD0486](https://sec-api.dev/pdufa/azd0486) (AZN)
- [Surovatamig](https://sec-api.dev/pdufa/surovatamig) (AZN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/large-b-cell-lymphoma.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "large B-cell lymphoma FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/large-b-cell-lymphoma

```bibtex
@misc{secapidev_indications_large_b_cell_lymphoma_20261116,
  title        = {large B-cell lymphoma FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/large-b-cell-lymphoma}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_large_b_cell_lymphoma_20261116","title":"large B-cell lymphoma FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/large-b-cell-lymphoma","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
